Pediatric malignant peripheral nerve sheath tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group

Modesto Carli, Andrea Ferrari, Adrian Mattke, Ilaria Zanetti, Michela Casanova, Gianni Bisogno, Giovanni Cecchetto, Rita Alaggio, Luigi De Sio, Eura Koscielniak, Guido Sotti, Joern Treuner

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Purpose: To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath tumors (MPNSTs) and to identify risk factors associated with outcome. Patients and Methods: A total of 167 untreated eligible patients enrolled onto the Italian and German studies between 1975 and 1998 entered this analysis. Seventeen percent of patients had neurofibromatosis type 1 (NF1). Chemotherapy was administered to 74% of patients; radiotherapy was administered to 38% of patients. Results: With a median follow-up of 7 years, 5-year overall survival (OS) and progression-free survival (PFS) were 51% and 37%, respectively. The 5-year OS and PFS by Intergroup Rhabdomyosarcoma Study (IRS) groupings were as follows: group I, 82% and 61%; group II, 62% and 37%; group III, 32% and 27%; group IV, 26% and 21%, respectively. Univariate analysis identified IRS groups, size, invasiveness, primary site, age, and presence of NF1 as prognostic factors; multivariate analysis identified absence of NF1, tumor invasiveness T1, IRS groups I to II and extremity of primary site as independent favorable factors for OS. A trend was observed toward a benefit from radiotherapy after initial gross resection. The overall response rate to primary chemotherapy, including minor responses, in group III patients was 45%. Conclusion: MPNST is an aggressive tumor for which complete surgical resection is the mainstay of successful treatment. Postoperative radiotherapy may have a role in improving local control in patients with minimal residual tumor. The reported responses to primary chemotherapy suggest that it may be effective in patients with tumor considered unresectable at diagnosis.

Original languageEnglish
Pages (from-to)8422-8430
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number33
DOIs
Publication statusPublished - 2005

Fingerprint

Neurilemmoma
Sarcoma
Pediatrics
Neurofibromatosis 1
Rhabdomyosarcoma
Radiotherapy
Drug Therapy
Disease-Free Survival
Survival
Neoplasms
Residual Neoplasm
Multivariate Analysis
Extremities

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pediatric malignant peripheral nerve sheath tumor : The Italian and German Soft Tissue Sarcoma Cooperative Group. / Carli, Modesto; Ferrari, Andrea; Mattke, Adrian; Zanetti, Ilaria; Casanova, Michela; Bisogno, Gianni; Cecchetto, Giovanni; Alaggio, Rita; De Sio, Luigi; Koscielniak, Eura; Sotti, Guido; Treuner, Joern.

In: Journal of Clinical Oncology, Vol. 23, No. 33, 2005, p. 8422-8430.

Research output: Contribution to journalArticle

Carli, M, Ferrari, A, Mattke, A, Zanetti, I, Casanova, M, Bisogno, G, Cecchetto, G, Alaggio, R, De Sio, L, Koscielniak, E, Sotti, G & Treuner, J 2005, 'Pediatric malignant peripheral nerve sheath tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group', Journal of Clinical Oncology, vol. 23, no. 33, pp. 8422-8430. https://doi.org/10.1200/JCO.2005.01.4886
Carli, Modesto ; Ferrari, Andrea ; Mattke, Adrian ; Zanetti, Ilaria ; Casanova, Michela ; Bisogno, Gianni ; Cecchetto, Giovanni ; Alaggio, Rita ; De Sio, Luigi ; Koscielniak, Eura ; Sotti, Guido ; Treuner, Joern. / Pediatric malignant peripheral nerve sheath tumor : The Italian and German Soft Tissue Sarcoma Cooperative Group. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 33. pp. 8422-8430.
@article{679b21b4fb3a41b68930239792abab2d,
title = "Pediatric malignant peripheral nerve sheath tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group",
abstract = "Purpose: To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath tumors (MPNSTs) and to identify risk factors associated with outcome. Patients and Methods: A total of 167 untreated eligible patients enrolled onto the Italian and German studies between 1975 and 1998 entered this analysis. Seventeen percent of patients had neurofibromatosis type 1 (NF1). Chemotherapy was administered to 74{\%} of patients; radiotherapy was administered to 38{\%} of patients. Results: With a median follow-up of 7 years, 5-year overall survival (OS) and progression-free survival (PFS) were 51{\%} and 37{\%}, respectively. The 5-year OS and PFS by Intergroup Rhabdomyosarcoma Study (IRS) groupings were as follows: group I, 82{\%} and 61{\%}; group II, 62{\%} and 37{\%}; group III, 32{\%} and 27{\%}; group IV, 26{\%} and 21{\%}, respectively. Univariate analysis identified IRS groups, size, invasiveness, primary site, age, and presence of NF1 as prognostic factors; multivariate analysis identified absence of NF1, tumor invasiveness T1, IRS groups I to II and extremity of primary site as independent favorable factors for OS. A trend was observed toward a benefit from radiotherapy after initial gross resection. The overall response rate to primary chemotherapy, including minor responses, in group III patients was 45{\%}. Conclusion: MPNST is an aggressive tumor for which complete surgical resection is the mainstay of successful treatment. Postoperative radiotherapy may have a role in improving local control in patients with minimal residual tumor. The reported responses to primary chemotherapy suggest that it may be effective in patients with tumor considered unresectable at diagnosis.",
author = "Modesto Carli and Andrea Ferrari and Adrian Mattke and Ilaria Zanetti and Michela Casanova and Gianni Bisogno and Giovanni Cecchetto and Rita Alaggio and {De Sio}, Luigi and Eura Koscielniak and Guido Sotti and Joern Treuner",
year = "2005",
doi = "10.1200/JCO.2005.01.4886",
language = "English",
volume = "23",
pages = "8422--8430",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - Pediatric malignant peripheral nerve sheath tumor

T2 - The Italian and German Soft Tissue Sarcoma Cooperative Group

AU - Carli, Modesto

AU - Ferrari, Andrea

AU - Mattke, Adrian

AU - Zanetti, Ilaria

AU - Casanova, Michela

AU - Bisogno, Gianni

AU - Cecchetto, Giovanni

AU - Alaggio, Rita

AU - De Sio, Luigi

AU - Koscielniak, Eura

AU - Sotti, Guido

AU - Treuner, Joern

PY - 2005

Y1 - 2005

N2 - Purpose: To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath tumors (MPNSTs) and to identify risk factors associated with outcome. Patients and Methods: A total of 167 untreated eligible patients enrolled onto the Italian and German studies between 1975 and 1998 entered this analysis. Seventeen percent of patients had neurofibromatosis type 1 (NF1). Chemotherapy was administered to 74% of patients; radiotherapy was administered to 38% of patients. Results: With a median follow-up of 7 years, 5-year overall survival (OS) and progression-free survival (PFS) were 51% and 37%, respectively. The 5-year OS and PFS by Intergroup Rhabdomyosarcoma Study (IRS) groupings were as follows: group I, 82% and 61%; group II, 62% and 37%; group III, 32% and 27%; group IV, 26% and 21%, respectively. Univariate analysis identified IRS groups, size, invasiveness, primary site, age, and presence of NF1 as prognostic factors; multivariate analysis identified absence of NF1, tumor invasiveness T1, IRS groups I to II and extremity of primary site as independent favorable factors for OS. A trend was observed toward a benefit from radiotherapy after initial gross resection. The overall response rate to primary chemotherapy, including minor responses, in group III patients was 45%. Conclusion: MPNST is an aggressive tumor for which complete surgical resection is the mainstay of successful treatment. Postoperative radiotherapy may have a role in improving local control in patients with minimal residual tumor. The reported responses to primary chemotherapy suggest that it may be effective in patients with tumor considered unresectable at diagnosis.

AB - Purpose: To assess the value of chemotherapy and radiotherapy in children with malignant peripheral nerve sheath tumors (MPNSTs) and to identify risk factors associated with outcome. Patients and Methods: A total of 167 untreated eligible patients enrolled onto the Italian and German studies between 1975 and 1998 entered this analysis. Seventeen percent of patients had neurofibromatosis type 1 (NF1). Chemotherapy was administered to 74% of patients; radiotherapy was administered to 38% of patients. Results: With a median follow-up of 7 years, 5-year overall survival (OS) and progression-free survival (PFS) were 51% and 37%, respectively. The 5-year OS and PFS by Intergroup Rhabdomyosarcoma Study (IRS) groupings were as follows: group I, 82% and 61%; group II, 62% and 37%; group III, 32% and 27%; group IV, 26% and 21%, respectively. Univariate analysis identified IRS groups, size, invasiveness, primary site, age, and presence of NF1 as prognostic factors; multivariate analysis identified absence of NF1, tumor invasiveness T1, IRS groups I to II and extremity of primary site as independent favorable factors for OS. A trend was observed toward a benefit from radiotherapy after initial gross resection. The overall response rate to primary chemotherapy, including minor responses, in group III patients was 45%. Conclusion: MPNST is an aggressive tumor for which complete surgical resection is the mainstay of successful treatment. Postoperative radiotherapy may have a role in improving local control in patients with minimal residual tumor. The reported responses to primary chemotherapy suggest that it may be effective in patients with tumor considered unresectable at diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=33644667931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644667931&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.01.4886

DO - 10.1200/JCO.2005.01.4886

M3 - Article

C2 - 16293873

AN - SCOPUS:33644667931

VL - 23

SP - 8422

EP - 8430

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -